26H0 Stock Overview
A neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Helius Medical Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.75 |
| 52 Week High | US$24.75 |
| 52 Week Low | US$0.40 |
| Beta | 1.11 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -84.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26H0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 4.5% | 1.2% |
| 1Y | -84.8% | -12.1% | 14.0% |
Return vs Industry: 26H0 underperformed the German Medical Equipment industry which returned -12.1% over the past year.
Return vs Market: 26H0 underperformed the German Market which returned 14% over the past year.
Price Volatility
| 26H0 volatility | |
|---|---|
| 26H0 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 26H0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 26H0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | Dane Andreeff | heliusmedical.com |
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non- implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc. Fundamentals Summary
| 26H0 fundamental statistics | |
|---|---|
| Market cap | €1.97m |
| Earnings (TTM) | -€11.72m |
| Revenue (TTM) | €389.25k |
5.2x
P/S Ratio-0.2x
P/E RatioIs 26H0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26H0 income statement (TTM) | |
|---|---|
| Revenue | US$434.00k |
| Cost of Revenue | US$580.00k |
| Gross Profit | -US$146.00k |
| Other Expenses | US$12.92m |
| Earnings | -US$13.06m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.74 |
| Gross Margin | -33.64% |
| Net Profit Margin | -3,010.14% |
| Debt/Equity Ratio | 0% |
How did 26H0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 00:47 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Helius Medical Technologies, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |
| Steven Lichtman | Oppenheimer & Co. Inc. |
| Andre Uddin | Research Capital Corporation |